Pilot: Sunitinib Malate for Advance Ocular Disease of Von Hippel-Lindau Syndrome

试点：苹果酸舒尼替尼治疗冯希佩尔-林道综合征晚期眼部疾病

• 批准号: 7976049
• 负责人: DARBY THOMPSON
• 金额: $ 14.2万
• 依托单位: THE EMMES COMPANY, LLC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-11-01 至 2011-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7976049
• 关键词: Pilot; Sunitinib; Malate; Advance; Ocular

Pilot Study of Sunitinib Malate for Advanced Ocular Disease of Von Hippel-Lindau Syndrome This study will determine if an experimental drug called sunitinib malate (Sutent) can help slow or stop the growth of eye angiomas (abnormal growth of blood vessels) in people with Von Hippel-Lindau (VHL) syndrome. VHL is a genetic disorder that increases production of body chemicals called vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF), which are important in the formation of new blood vessels.

苹果酸苏尼替尼治疗晚期Von Hippel-Lindau综合征眼病的初步研究 这项研究将确定一种名为苹果酸舒尼替尼(Sutent)的实验性药物是否有助于减缓或阻止冯·希佩尔-林道(VHL)综合征患者眼部血管瘤(血管的异常生长)的生长。VHL是一种遗传性疾病，它会增加体内称为血管内皮生长因子(VEGF)和血小板衍生生长因子(PDGF)的化学物质的产生，这两种物质在新血管的形成中起着重要作用。